Antengene Corp. has appointed John Chin as chief business officer, responsible for the company’s global business development and commercialization. He reports to Dr. Jay Mei, chairman and chief executive officer of Antengene.

Mr. John Chin has 30 years of pharmaceutical industry experience. Prior to joining Antengene, he was country general manager at Celgene China, leading a cross-functional team to support the development and approval of Celgene assets as well as approved brands commercialized by its partners in China. He spent 15 years at Celgene, held senior positions at Celgene and Aventis and previously worked at BMS and Merck.

John has launched and managed some of the most important oncology therapies ever introduced into the U.S., Latin American and Chinese markets. While at Celgene from 2005 through 2019, he was instrumental in the commercial launch and lifecycle management of REVLIMID, one of the industry’s most successful global hematology products. He also held key roles in the global management of the entire Celgene cancer portfolio.

“Antengene has made tremendous progress and is ready to begin building a world-class commercial team while continuing to add clinical and commercial-stage cancer products to our strong pipeline. We are currently building our commercial operations to support the launch of ATG-010 (selinexor) in China for the treatment of adult patients with relapsed or refractory multiple myeloma, and are actively seeking more global opportunities to expand our commercial pipeline,” said Dr. Jay Mei, chairman and chief executive officer of Antengene. “We are thrilled that John is joining us now as his proven strategic and operational business development skills will further strengthen our ability to deliver meaningful results now and in the future.”

“Antengene Corporation has already established a unique vision in which it seeks to treat patients beyond borders,” said Mr. Chin. “I am impressed with Antengene’s broad pipeline and highly capable R&D team, and look forward to working with Dr. Mei to rapidly build Antengene’s commercial and operational capabilities so that we can become a premier global cancer company in the near future.”